{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:30:13Z","timestamp":1760056213021,"version":"build-2065373602"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Current World Health Organization (WHO) 2021 classification of adult-type diffuse gliomas includes three main diagnostic entities with different prognosis and treatment algorithm: glioblastoma IDH wild-type, astrocytoma IDH mutant, and oligodendroglioma IDH mutant\/1p-19q co-deleted. For IDH mutant gliomas, it is well known that administering postoperative chemo-radiation based on risk factors such as age, extent of resection, and WHO grading significantly improves disease control and overall survival. However, whether the use of chemotherapy may be considered safe in special populations such as orthotopic liver transplant recipients (TRs) is still not fully understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>Here, we report the case of a 56-year-old patient diagnosed with central nervous system WHO grade 2 oligodendroglioma IDH mutant\/1p-19q co-deleted and medical history of orthotopic liver transplantation for HCV-related cirrhosis, subsequent HCV infection relapse and on therapy with immunosuppressive agents (tacrolimus plus everolimus). After radiation therapy, benefits and risks of chemotherapy were carefully assessed in terms of drug-to-drug interactions, additive immune-suppression, potential hepatic toxicity, and possibility of organ rejection. The patient successfully received a full course of standard-schedule temozolomide for 12 cycles, with no adverse events to be reported. Notably, imaging findings consistent with treatment-related changes were observed during chemotherapy cycles, managed with appropriate diagnostic workflow and no treatment interruption.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This case study described for the first time safe administration of temozolomide-based chemotherapy in an orthotopic TR, sharing potential insights for best managing such a rare clinical scenario.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npaf034","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:18:17Z","timestamp":1742714297000},"page":"922-927","source":"Crossref","is-referenced-by-count":0,"title":["Case study: Successful full-course chemotherapy administration in a liver transplant recipient diagnosed with central nervous system World Health Organization Grade 2 IDH mutant\/1p-19q co-deleted oligodendroglioma"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-8156","authenticated-orcid":false,"given":"Angelo","family":"Dipasquale","sequence":"first","affiliation":[{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnese","family":"Losurdo","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Persico","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Aimola","sequence":"additional","affiliation":[{"name":"Neuroradiology Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethania","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Pathology Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan ,","place":["Italy"]},{"name":"Nucler Medicine Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-1251","authenticated-orcid":false,"given":"Matteo","family":"Simonelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan ,","place":["Italy"]},{"name":"Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"8","key":"2025100904421527100_CIT0001","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025100904421527100_CIT0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/noac207","article-title":"Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions","volume":"25","author":"Miller","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025100904421527100_CIT0003","doi-asserted-by":"crossref","first-page":"e431450","DOI":"10.1200\/EDBK_431450","article-title":"State of the art in low-grade glioma management: insights from isocitrate dehydrogenase and beyond","volume":"44","author":"Schaff","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"14","key":"2025100904421527100_CIT0004","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med."},{"issue":"1","key":"2025100904421527100_CIT0005","doi-asserted-by":"crossref","first-page":"e14841","DOI":"10.1111\/ctr.14841","article-title":"Antineoplastic chemotherapy and immunosuppression in liver transplant recipients: squaring the circle","volume":"37","author":"Coupier","year":"2023","journal-title":"Clin Transplant."},{"issue":"6","key":"2025100904421527100_CIT0006","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/lt.21727","article-title":"Graft rejection occurring in post-liver transplant patients receiving cytotoxic chemotherapy: a case series","volume":"15","author":"Tan","year":"2009","journal-title":"Liver Transpl."},{"issue":"6","key":"2025100904421527100_CIT0007","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cgh.2013.10.034","article-title":"Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals","volume":"12","author":"Mahale","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"10103","key":"2025100904421527100_CIT0008","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S0140-6736(17)32438-8]","article-title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study [published correction appears in Lancet","volume":"390","author":"van den Bent","year":"2017","journal-title":"Lancet."},{"issue":"7","key":"2025100904421527100_CIT0009","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol."},{"issue":"1","key":"2025100904421527100_CIT0010","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3747\/co.25.3680","article-title":"Procarbazine, lomustine and vincristine toxicity in low-grade gliomas","volume":"25","author":"Jutras","year":"2018","journal-title":"Curr Oncol"},{"issue":"6","key":"2025100904421527100_CIT0011","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1007\/s10637-011-9775-5","article-title":"A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study","volume":"30","author":"Mason","year":"2012","journal-title":"Invest New Drugs."},{"issue":"5","key":"2025100904421527100_CIT0012","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1002\/onco.13701","article-title":"Radiotherapy plus procarbazine, lomustine, and vincristine versus radiotherapy plus temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicenter analysis of the French POLA cohort","volume":"26","author":"Martin","year":"2021","journal-title":"Oncologist."},{"issue":"6","key":"2025100904421527100_CIT0013","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nor040","article-title":"International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors","volume":"13","author":"Lassman","year":"2011","journal-title":"Neuro Oncol"},{"issue":"11","key":"2025100904421527100_CIT0014","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/neuonc\/now228","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"issue":"3","key":"2025100904421527100_CIT0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.24.00049","article-title":"Survival outcomes associated with first-line procarbazine, CCNU, and vincristine or temozolomide in combination with radiotherapy in IDH-Mutant 1p\/19q-codeleted grade 3 oligodendroglioma","volume":"43","author":"Kacimi","year":"2025","journal-title":"J Clin Oncol."},{"issue":"11","key":"2025100904421527100_CIT0016","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"29","key":"2025100904421527100_CIT0017","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2006.06.3891","article-title":"Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study","volume":"24","author":"Brandes","year":"2006","journal-title":"J Clin Oncol."},{"issue":"10","key":"2025100904421527100_CIT0018","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1470-2045(07)70315-7","article-title":"Management of solid tumours in organ-transplant recipients","volume":"8","author":"Ajithkumar","year":"2007","journal-title":"Lancet Oncol."},{"key":"2025100904421527100_CIT0019","doi-asserted-by":"crossref","first-page":"109674","DOI":"10.1016\/j.radonc.2023.109674","article-title":"Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma","volume":"184","author":"Jaspers","year":"2023","journal-title":"Radiother Oncol."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf034\/62523150\/npaf034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/5\/922\/62523150\/npaf034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/5\/922\/62523150\/npaf034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:43:16Z","timestamp":1759999396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/12\/5\/922\/8090341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,22]]},"published-print":{"date-parts":[[2025,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf034","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,3,22]]}}}